NCT02378688

Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary objectives of the study are: * To evaluate the safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD） * To evaluate the clinical efficacy of MT-1303 in subjects with moderate to severe active CD.

Conditions

• Crohn's Disease

Interventions

Type	Name	Description
DRUG	MT-1303
DRUG	Placebo

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2015-03-04
• Last updated: 2016-10-14

Locations

11 sites across 11 countries: Czechia, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Slovakia, Ukraine